lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024

Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw

• MoonLake Immunotherapeutics Announces Positive Regulatory Feedback From Both FD…

BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1

• Bispecific T cell engager therapy for refractory rheumatoid arthritis

9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024

Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd

• Tapering Treatment for Lupus | RheumNow

Cognitive Function in Older Adults: Worse in Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk

• Cognitive Function in Older Adults: Worse in Lupus | RheumNow

A Puzzling Era in Global Drug Development? Dr. Eric Ruderman offers his observation regarding a puzzling global drug development observation, at Eular 2024 in Vienna, Austria. https://t.co/A4KQovIt3u https://t.co/TQHJnSkIod

• A Puzzling Era in Global Drug Development? | RheumNow

Be-GIANT cohort, 44.3% pts met definition of early axSpA (<2 yr Sxs). early axSpA had younger age and lower frequency of radiographic sacroiliitis. MDs think early disease to be more severe with higher physician global than late axSpA @synovialjoints #EULAR2024 Abstract POS0443 https://t.co/97J9tg0XZg

FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw

• FDA approves sarilumab to treat active polyarticular juvenile idiopathic arthri…

Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

• Rinvoq Approved for Pediatric Patients With pJIA, Psoriatic Arthritis

Work ability impaired in majority of axSpA measured by the WAI score. 996 pts w a mean WAI score of 31.7. Overall, 28%/43%pts were in poor/moderate work ability, older, more often obese, w/ lower education, & phys work @synovialjoints #EULAR2024 Abstract POS0437 @RheumNow https://t.co/rQ4BunCn6T

Systemic Score in AOSD to Predict Life-threatening Complications Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria. https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2

• Systemic Score in AOSD to Predict Life-threatening Complications | RheumNow

The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria. https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f

• The Crossroads of Autoinflammation and Autoimmunity | RheumNow

The path to new technologies in rheumatology must be beset with caution https://t.co/rostCE3UFT https://t.co/bn352RmrN8

• The path to new technologies in rheumatology must be beset with caution | Rheum…